GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 9 Meters Biopharma Inc (OTCPK:NMTRQ) » Definitions » Current Ratio

9 Meters Biopharma (9 Meters Biopharma) Current Ratio : 0.59 (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is 9 Meters Biopharma Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. 9 Meters Biopharma's current ratio for the quarter that ended in Mar. 2023 was 0.59.

9 Meters Biopharma has a current ratio of 0.59. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If 9 Meters Biopharma has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for 9 Meters Biopharma's Current Ratio or its related term are showing as below:

NMTRQ's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.71
* Ranked among companies with meaningful Current Ratio only.

9 Meters Biopharma Current Ratio Historical Data

The historical data trend for 9 Meters Biopharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

9 Meters Biopharma Current Ratio Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.35 5.68 5.91 1.08

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.75 3.36 1.43 1.08 0.59

Competitive Comparison of 9 Meters Biopharma's Current Ratio

For the Biotechnology subindustry, 9 Meters Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


9 Meters Biopharma's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Current Ratio falls into.



9 Meters Biopharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

9 Meters Biopharma's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=33.018/30.696
=1.08

9 Meters Biopharma's Current Ratio for the quarter that ended in Mar. 2023 is calculated as

Current Ratio (Q: Mar. 2023 )=Total Current Assets (Q: Mar. 2023 )/Total Current Liabilities (Q: Mar. 2023 )
=9.197/15.577
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


9 Meters Biopharma  (OTCPK:NMTRQ) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


9 Meters Biopharma Current Ratio Related Terms

Thank you for viewing the detailed overview of 9 Meters Biopharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


9 Meters Biopharma (9 Meters Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.
Executives
Bethany Sensenig officer: Chief Financial Officer C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
John Temperato director, officer: Chief Executive Officer C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Samantha Ventimiglia director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Edward J Sitar officer: Chief Financial Officer 39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Orbimed Israel Biofund Gp Limited Partnership 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Yehuda Michael Rice director 155 WALNUT STREET, ENGLEWOOD NJ 07631
Nissim Darvish director, 10 percent owner C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Orbimed Israel Gp Ltd. 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Sandeep Laumas director, officer: Executive Chairman 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Jay P. Madan director, officer: President 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Roy Proujansky director 144 PAU NEL DRIVE, LANDENBERG PA 19350
Christopher P. Prior director, officer: Chief Executive Officer 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
June Sherie Almenoff officer: COO and Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019